(Q36567768)

English

Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus

scientific article published on January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus (English)

1 reference

Europe PubMed Central

15 August 2017

vascular disease

1 reference

based on heuristic

inferred from title

author name string

Ramón Ríos-Vázquez

1

1 reference

Europe PubMed Central

15 August 2017

Raquel Marzoa-Rivas

2

1 reference

Europe PubMed Central

15 August 2017

Ignacio Gil-Ortega

3

1 reference

Europe PubMed Central

15 August 2017

Juan Carlos Kaski

4

1 reference

Europe PubMed Central

15 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2006

1 reference

Europe PubMed Central

15 August 2017

American journal of cardiovascular drugs

1 reference

Europe PubMed Central

15 August 2017

6

1 reference

Europe PubMed Central

15 August 2017

4

1 reference

Europe PubMed Central

15 August 2017

231-242

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.2165/00129784-200606040-00003

0 references

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

PPARgamma in the control of brown adipocyte differentiation.

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Reactive oxygen species, metalloproteinases, and plaque stability.

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Platelet functions in diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men.

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Troglitazone improves endothelial dysfunction in patients with insulin resistance.

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Troglitazone and small low-density lipoprotein in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.2165%2F00129784-200606040-00003

21 January 2018

Identifiers

10.2165/00129784-200606040-00003

1 reference

Europe PubMed Central

15 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36567768&oldid=1638266561"